Wells Fargo’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-53,628
Closed -$1.5M 7025
2019
Q3
$1.5M Sell
53,628
-3,663
-6% -$59.3K ﹤0.01% 3558
2019
Q2
$808K Sell
57,291
-32,445
-36% -$309K ﹤0.01% 4047
2019
Q1
$798K Sell
89,736
-36,760
-29% -$298K ﹤0.01% 4042
2018
Q4
$959K Sell
126,496
-141,544
-53% -$2.28M ﹤0.01% 3878
2018
Q3
$5.62M Sell
268,040
-112,415
-30% -$2.68M ﹤0.01% 2556
2018
Q2
$11.4M Buy
380,455
+42,819
+13% +$1.17M ﹤0.01% 1965
2018
Q1
$9.16M Buy
337,636
+20,713
+7% +$620K ﹤0.01% 2093
2017
Q4
$9.13M Sell
316,923
-7,364
-2% -$202K ﹤0.01% 2067
2017
Q3
$7.87M Buy
324,287
+124,287
+62% +$2.95M ﹤0.01% 2150
2017
Q2
$4.46M Buy
+200,000
New +$4.21M ﹤0.01% 2550

Wells Fargo's DOVA Position: Q4 2019 in Review

Wells Fargo sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2019, closing a stake of 53,628 shares — an estimated $1.5M sold.

Wells Fargo first reported a position in DOVA in Q2 2017 and held it in 10 quarters. The position peaked at $11.4M in Q2 2018. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • Wells Fargo reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Wells Fargo sold 53,628 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $1.5M.
  • Wells Fargo first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 10 quarters.
  • Wells Fargo's Dova Pharmaceuticals, Inc. Common Stock position peaked at $11.4M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Wells Fargo's 13F filing for Q4 2019, filed 14 Feb 2020.